07:45 AM EDT, 06/30/2025 (MT Newswires) -- INmune Bio ( INMB ) shares were 59% lower pre-bell Monday after the company said that a phase 2 trial of its treatment candidate for Alzheimer's disease failed to meet the primary cognitive endpoint in the intent-to-treat population.

Blue Gold ( BGL ) shares were 24% lower, paring Friday's rally.

Locafy ( LCFY ) stock was down 17%, shaving gains from the previous session.